HSDT (heliusmedical.com) Market Value to Book Value Ratio

Official company branding of heliusmedical.com (HSDT)

Helius Medical (HSDT) is developing neurostimulation technologies, however, slow recognition by insurance companies is limiting PoNS sales, which keeps the operating leverage at 0.77. The business relies on strict medical oversight when transporting equipment to therapy centers. This daily price action is presented below, while the company is reducing capital expenditures by outsourcing device assembly to third-party contractors.

HSDT - Helius Medical Technologies, Inc. Market-to-Book Ratio over the range 07/04/2022 - 10/27/2026
Original product of heliusmedical.com

This indicator compares the current market value of Helius Medical (HSDT) to its net assets, determining the premium or discount to capital. By analyzing the change in the market value to book capitalization ratio, an investor assesses the real value of the business relative to accounting data. For Helius Medical, this balance reflects market confidence in the expansion of insurance coverage for neurostimulation systems. The stability of the line confirms the company's fundamental resilience, while the absence of sharp spikes eliminates the risk of hidden asset impairment.

Competitor analysis

BIIB - Market Cap to Net Assets Ratio|NBIX (neurocrine.com) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|AMLX - Market Capitalization to Book Value Ratio|Market Value to Book Value trevitherapeutics.com|Praxis Precision Medicines, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio AVXL (Anavex)|Market Value to Book Value Ratio CeriBell Corp CBLL|Market Value to Book Value Ratio Prothena PRTA|Market Capitalization to Book Value Ratio ALEC (Alector Therapeutics)|annexonbio.com (ANNX) - Market Capitalization to Book Value|OMER: Market Cap to Net Assets Ratio|NGNE (Neurogene Inc) - Market Capitalization to Book Value Ratio|ACIU: Market Value to Book Value Ratio|Market Capitalization to Book Value Voyager Corp (VYGR)|Neumora Therapeutics (NMRA) - Market Cap to Net Assets Ratio|Market Value to Book Value SCLX (scilexholding.com)|Tevogen Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Alpha Cognition Inc ACOG|CGTX (Cognition Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|IKT - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Cassava Sciences, Inc.|Assertio (ASRT) - Capitalization to Book Value Ratio|COYA: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value VistaGen Therapeutics Inc|Market Capitalization to Book Value Ratio OVID (Ovid Therapeutics Inc.)|Market Cap to Net Assets Ratio Acumen Pharmaceuticals, Inc (ABOS)|Market Capitalization to Book Value Ratio CRVO (CervoMed Inc.)|Alterity Therapeutics Ltd. - Market Capitalization to Book Value Ratio|CLNN - Market Value to Book Value Ratio|PEPG - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio Jupiter Neurosciences JUNS|RLMD (Relmada Corp) - Market Value to Book Value|ANVS: Market Value to Book Value Ratio|Market Capitalization to Book Value Grace Tx|Market Capitalization to Book Value Ratio Firefly Neuroscience AIFF|Capitalization to Book Value Ratio anewmeds.com KLTO|Market Cap to Net Assets Ratio NeuroSense Therapeutics Ltd. (NRSN)|Reviva Pharmaceuticals, Inc. - Market Cap to Book Value Multiple|MetaVia, Inc. (MTVA) - Market Value to Book Value Ratio|NRXS - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PASG|Market-to-Book Ratio Neuphoria Therapeutics|NERV (Minerva Neurosciences Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ATHA|Addex Therapeutics (ADXN) - Market Value to Book Value Ratio|Market Value to Book Value ALZN (alzamend.com)|CYCN: Market Value to Book Value Ratio|Market-to-Book Ratio Protagenic Therapeutics Inc. PTIX|Market Capitalization to Book Value Ratio Pasithea (KTTA)|CRGT - Market Value to Book Value|Market Capitalization to Book Value Ratio ATXI|BCLI (brainstorm-cell.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Cara Therapeutics|Market Value to Book Value Ratio Chromocell Therapeutics Corp|ELYM (Eliem Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value intracellulartherapies.com ITCI|Market Cap to Net Assets Ratio LBPH (Longboard Pharmaceuticals)|marinuspharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NKGN (NKGen Biotech)|NeuroBo Pharmaceuticals Inc (NRBO) - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Sage Therapeutics, Inc SAGE|SNPX (Synaptogenix, Inc) - Market Value to Book Value|Market Value to Book Value Ratio TRVN|Market Cap to Net Assets Ratio Vigil Neuro|Anew Medical, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Cerevel Therapeutics Inc (CERE)